Close
18/03/2014
The public-private partnership ESTEVE-UAB is bearing fruit
ESTEVE has announced the signing of two agreements that will enable it to progress the development of its gene therapeutic for the treatment of Sanfilippo A Syndrome and begin a phase I/II clinical trial in 2015. The agreements are with the North American biotechnology company REGENX Biosciences, LLC (REGENX) and with the French non for profit organization GÉNÉTHON.
 
Sanfilippo A is a rare and devastating neurodegenerative disease that affects approximately 1 in every 100.000 children that rarely survive past adolescence.

This gene therapy program is being developed in a public-private partnership between ESTEVE and the research team of Dr. Fàtima Bosch at the Center for Biotechnology and Gene Therapy of the Universitat Autònoma de Barcelona (UAB).

In this partnership, ESTEVE leads all activities associated with the management and protection of intellectual property, regulatory activities, the coordination and supervision of GMP manufacturing, the preclinical toxicology studies as well as all clinical development.
The CBATEG research team at the UAB brings to the partnership their scientific know-how and expertise in gene therapy including viral vector design and the development of preclinical disease models.

Press release

More news

02/06/2021 Parc de l’Alba in a WHO publication on the redevelopment of contaminated sites 27/04/2021 Natura Bissé: when architecture reflects the brand identity 08/04/2021 ASTIP, the future hub for advanced research in the Barcelona Synchrotron Park 25/03/2021 4th anniversary of the setting up of Stradivarius headquarter in the Barcelona Synchrotron Park 05/03/2021 T-Systems, a leading IT service provider with a Data Centre in the Barcelona Synchrotron Park 18/02/2021 SENER participates in the Perseverance rover which is landing on Mars today
1 2 3 4 5 6 7